{
  "nctId": "NCT05393232",
  "briefTitle": "Groceries for Black Residents of Boston to Stop Hypertension Among Adults With Treated Hypertension",
  "officialTitle": "Effects of DASH Groceries on Blood Pressure in Black Residents of Urban Food Deserts With Treated Hypertension",
  "protocolDocument": {
    "nctId": "NCT05393232",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2025-08-11",
    "uploadDate": "2025-08-11T07:05",
    "size": 1578589,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT05393232/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 150,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2022-10-13",
    "completionDate": "2025-10",
    "primaryCompletionDate": "2025-08",
    "firstSubmitDate": "2022-05-23",
    "firstPostDate": "2022-05-26"
  },
  "eligibilityCriteria": {
    "criteria": "INCLUSION:\n\n* Self-reported/self-identified as Black or African American\n* Resting systolic blood pressure of 120 to \\<150 mm Hg and diastolic blood pressure \\<100 mm Hg\n* Active treatment with medications intended for hypertension treatment within the last 6 months at stable doses\n* Residence in communities identified as Boston area food deserts: Brighton, Chelsea, Dorchester, East Boston, Everett, Hyde Park, Jamaica Plain, Malden, Mattapan, Revere, Roslindale, Roxbury, or Winthrop\n* Able to receive home-delivered groceries or pick them up at a convenient location and willing to eat only the groceries provided over a 12-week period\n* Have access to refrigeration, cooking appliances, and Wi-Fi/cellular service\n* Have access to mobile device or computer to be able to conduct grocery orders via video conference or by phone\n* Willing and able to complete required measurement procedures\n\nEXCLUSION:\n\nLaboratory Exclusions:\n\n* Serum potassium ≥5.0 mmol/L or \\<3.5 mmol/L\n* Estimated glomerular filtration rate (eGFR) \\<30 mL/min per 1.73 m\\^2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation\n* Hemoglobin A1c ≥6.5%\n\nMedication Exclusions:\n\n* Unstable doses of medications that lower blood pressure or medications intended for hypertension treatment (including antihypertensives taken for non-hypertension purposes) within the last 6 months\n* Unstable doses (i.e. a change in the 2 months prior to screening or randomization) of the following:\n\n  * Sodium-glucose co-transporter 2 (SGLT2) inhibitors\n  * Stimulants\n  * Inhaled or oral medications for asthma or chronic obstructive pulmonary disease (COPD)\n  * Hormone replacement therapy or thyroid hormone\n  * Weight-increasing psychotropic agents, including antipsychotic agents, lithium, and mirtazapine\n* Use of any of the following medications:\n\n  * Potassium supplement, except if part of a multivitamin\n  * Warfarin (Coumadin)\n  * Chronic oral corticosteroid (intermittent use is okay)\n  * Weight loss medications (including GLP-1 receptor agonists)\n* Unwillingness to keep same dose of vitamin, mineral, and botanical supplements\n* Any medication not compatible with participation as determined by the investigators\n\nPhysical Exclusions:\n\n* Systolic blood pressure ≥150 mm Hg or diastolic blood pressure ≥100 mm Hg\n* Body weight \\>420 pounds\n* Arm circumference \\>50cm\n* Weight loss or gain of \\>5.0% of body weight during prior 2 months\n\nMedical History Exclusions:\n\n* Type 1 or Type 2 Diabetes defined as a hemoglobin A1c ≥6.5% or diabetes treatment\n* Active cardiovascular disease or any event in the prior 6 months, including coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) exacerbation requiring hospital admission\n* Cancer diagnosis or treatment in the last 2 years (non-melanoma skin cancer or localized breast or prostate or bladder cancer not requiring systemic therapy is acceptable)\n* Active inflammatory bowel disease, bowel resection, malabsorptive syndrome, pancreatitis (episode within past year), or history of bariatric surgery\n* Pregnancy or lactation or planned pregnancy\n* Any emergency department (ED) visit for asthma or chronic obstructive pulmonary disease (COPD) in the last 6 months\n* Any other serious illness or condition not compatible with participation as determined by the investigators\n\nLifestyle and Other Exclusions:\n\n* Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence\n* Consumption of more than 14 alcoholic drinks per week or consumption of more than 6 drinks on one or more occasion per week\n* Active substance use disorder that would interfere with participation\n* Extreme food insecurity\n* Participation in or planning to start weight loss program\n* Current participation in another clinical trial that could interfere with the study protocol\n* Anticipated change in residence prior to the end of the study\n* Families with more than 6 adults at dinner time (children are considered to be half an adult)\n* Investigator discretion",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "100 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Seated, office-based, systolic blood pressure (intervention phase)",
        "description": "In-person, measured with an automated oscillometric device that will perform 3 measurements.",
        "timeFrame": "Measured 3 months after randomization"
      }
    ],
    "secondary": [
      {
        "measure": "Seated, office-based, systolic blood pressure (observation phase)",
        "description": "In-person, measured with an automated oscillometric device that will perform 3 measurements.",
        "timeFrame": "Measured 6 months after randomization"
      },
      {
        "measure": "Seated, office-based, diastolic blood pressure (intervention & observation phases)",
        "description": "In-person, measured with an automated oscillometric device that will perform 3 measurements.",
        "timeFrame": "Measured 3 and 6 months after randomization"
      },
      {
        "measure": "Ambulatory blood pressure monitoring: wake-time systolic and diastolic blood pressure (intervention & observation phases)",
        "description": "Ambulatory blood pressure monitoring with a mobile blood pressure device that will measure blood pressure over a 24-hour period.",
        "timeFrame": "Measured 3 and 6 months after randomization"
      },
      {
        "measure": "Body Mass Index (BMI) (intervention & observation phases)",
        "description": "In-person, measurement based on height and weight. Height is measured via a stadiometer and weight is measured via calibrated scale.",
        "timeFrame": "Measured 3 and 6 months after randomization"
      },
      {
        "measure": "24-hour urine potassium (intervention & observation phases)",
        "description": "Collected at home after a clinic void over a 24-hour period",
        "timeFrame": "Measured 3 and 6 months after randomization"
      },
      {
        "measure": "24-hour urine sodium (intervention & observation phases)",
        "description": "Collected at home after a clinic void over a 24-hour period",
        "timeFrame": "Measured 3 and 6 months after randomization"
      },
      {
        "measure": "Hemoglobin A1c (intervention & observation phases)",
        "description": "In-person blood collection; measure of glycemia over the preceding 3 months",
        "timeFrame": "Measured 3 and 6 months after randomization"
      },
      {
        "measure": "Lipids (intervention & observation phases)",
        "description": "Measured in fasted serum specimens collected during phlebotomy. Includes total cholesterol, high density lipoprotein cholesterol, derived low density lipoprotein cholesterol, and triglycerides",
        "timeFrame": "Measured 3 and 6 months after randomization"
      },
      {
        "measure": "Serum potassium (intervention & observation phases)",
        "description": "Measured in blood as part of a basic metabolic panel",
        "timeFrame": "Measured 3 and 6 months after randomization"
      },
      {
        "measure": "Serum creatinine (intervention & observation phases)",
        "description": "Measured in blood as part of a basic metabolic panel",
        "timeFrame": "Measured 3 and 6 months after randomization"
      },
      {
        "measure": "Daily intake of fat, fruits, and vegetables (intervention & observation phases)",
        "description": "Assessed via questionnaire in-person and via phone call; assessed via a validated food screener (Block et al; PMID: 10788730).",
        "timeFrame": "Measured 3, 6, and 12 months after randomization"
      },
      {
        "measure": "24-hour dietary recall (intervention & observation phases)",
        "description": "Assessed via questionnaire in-person using the Automated Self-Administered 24-Hour Dietary Recall (ASA24)",
        "timeFrame": "Measured 3 and 6 months after randomization"
      }
    ],
    "other": [
      {
        "measure": "Qualitative Interviews",
        "description": "The investigators will perform qualitative interviews in a subpopulation of both study assignments to assess for barriers and facilitators related to long-term maintenance of the intervention.",
        "timeFrame": "6 months after randomization"
      },
      {
        "measure": "Short Form 12 Item Health Survey (SF-12)",
        "description": "Assessment of global health-related quality of life",
        "timeFrame": "Measured 3, 6, and 12 months after randomization"
      },
      {
        "measure": "Grocery shopping and dining habits",
        "description": "This is a modified version of the interviewer-administered SHoPPER (Study of Household Purchasing Patterns, Eating, and Recreation) instrument (French et al; PMID: 30808311) with some modifications to assess grocery shopping, meal preparation, and dining behaviors and habits.",
        "timeFrame": "Measured 3, 6, and 12 months after randomization"
      },
      {
        "measure": "Perceived Stress Scale 4 (PSS-4)",
        "description": "An instrument used to assess participants' feelings about stress",
        "timeFrame": "Measured 3, 6, and 12 months after randomization"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 12,
      "otherCount": 4,
      "totalCount": 17
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:15.370Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}